PharmaTher Introduces PatchPrint With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
PharmaTher Expands PharmaPatch Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Quebec Innovative Materials Corp. Announces U.S. Affiliate Orvian Receives Minnesota DNR Registration for Exploratory Boring
